Hostname: page-component-669899f699-8p65j Total loading time: 0 Render date: 2025-05-02T09:05:29.207Z Has data issue: false hasContentIssue false
  • English
  • Français

The clinical usefulness of oestrogen-receptor and other markers of hormone dependence

Published online by Cambridge University Press:  05 December 2011

Gary M. Clark  and
William L. McGuire
Gary M. Clark
Affiliation:
Department of Medicine/Oncology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78284–7884, U.S.A.
William L. McGuire
Affiliation:
Department of Medicine/Oncology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78284–7884, U.S.A.
Get access

Synopsis

There is an increasing trend to administer adjuvant therapy to patients with all stages of primary breast cancer. However, since only about half of these patients will eventually relapse, it would be useful to have a set of factors that could predict which patients are at high risk for recurrence and which patients are probably cured by local therapy alone.

Using tumour specimens from our San Antonio Tumour Bank, we have confirmed the prognostic significance of axillary nodal status for predicting disease-free and overall survival. Among patients with node-positive disease, both oestrogen-receptors (ER) and progesterone-receptors (PgR) are predictive of patient outcome, but PgR is the more powerful factor. Using multivariate techniques, we have found that amplification and/or expression of the HER-2/neu oncogene provides additional prognostic information for node-positive patients.

Among patients with node-negative disease, ER and tumour size comprise a powerful set of prognostic factors. But ploidy status and S-phase fraction, as measured by flow cytometry, provide additional independent information for predicting disease-free and overall survival. Using these factors, sub-groups of node-negative patients with low risk of recurrence who will probably not benefit from adjuvant systemic therapy might be identified.

Type
Research Article
Information
Proceedings of the Royal Society of Edinburgh, Section B: Biological Sciences , Volume 95: Oestrogen and the Human Breast , 1989 , pp. 145 - 150
Copyright
Copyright © Royal Society of Edinburgh 1989

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Clark, G. M., McGuire, W. L., Hubay, C. A., Pearson, O. H. & Marshall, J. S. 1983. Progesterone receptor as a prognostic factor in Stage II breast cancer. New England Journal of Medicine 309, 1343–1347.CrossRefGoogle ScholarPubMed
Clark, G. M., Osborne, C. K. & McGuire, W. L. 1984. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. Journal of Clinical Oncology 2, 1102–1109.CrossRefGoogle ScholarPubMed
Clark, G. M., Sledge, G. W. Jr., Osborne, C. K. & McGuire, W. L. 1987. Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patients. Journal of Clinical Oncology 5, 55–61.CrossRefGoogle Scholar
Clark, G. M., Dressler, L. G., Owens, M. A., Pounds, G., Oldaker, T. & McGuire, W. L. 1989. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. New England Journal of Medicine 320, 627–633.CrossRefGoogle ScholarPubMed
Dressler, L., Seamer, L. C., Owens, M. A., Clark, G. M. & McGuire, W. L. 1988. DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer 61, 420–427.3.0.CO;2-0>CrossRefGoogle ScholarPubMed
McGuire, W. L., De La Garza, M. & Chamness, G. C. 1977. Evaluation of estrogen receptor assays in human breast cancer tissue. Cancer Research 37, 637–639.Google Scholar
Powell, B., Garola, R. E., Chamness, G. C. & McGuire, W. L. 1979. Measurement of progesterone receptor in human breast cancer biopsies. Cancer Research 39, 1678–1682.Google ScholarPubMed
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A. & McGuire, W. L. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–182.Google Scholar
Slamon, D. J. & Clark, G. M. 1988. Response to technical comment. Science 240, 1796–1798.CrossRefGoogle Scholar
Tandon, A., Clark, G., Ullrich, A., Slamon, D. & McGuire, W. 1988. Over-expression of the HER-2/neu oncogene predicts relapse and survival in stage II human breast cancers. Proceedings of the American Society of Clinical Oncology 7, 14.Google Scholar